Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Sirona Biochem Corp > I'm surprised there hasn't been more discussion about this..
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(4)
•••
Comment by str8goods4achgon Jan 26, 2024 5:06pm
95 Views
Post# 35847921

RE:RE:RE:RE:I'm surprised there hasn't been more discussion about this..

RE:RE:RE:RE:I'm surprised there hasn't been more discussion about this..100% correct - that is one of the benefits for two legally separate enties. 

I was thinking more about how existing SBM shareholders have been subordinated and the distribution of $ upon a theoretical bankrupcy. SBM investors are still last in line, but the line just got larger with the insertion of SL creditors. 

We've seen how SBM management rewards themselves... taking value out of SBM through large bonuses. Now we have 2 levels of this... for starters.

If you believe AA is the miracle molecule to make all these years of waiting worthwhile... you want to hold SL shares more than SBM shares. We've not been given that chance.

I'm surprised you seem to be ok with this latest shell game move. 

I've raised my concern and said my peace.

GLTA
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities